And this is what drives Eben Bayer crazy. Cofounder and CEO of Ecovative Design, Bayer is on a mission to replace all packaging foam with a new material made from agricultural byproducts and mushrooms.
Bayer and his cofounder invented Mycobond a patent-pending technology that uses a growing organism and byproducts from food production (oat hulls from New york, cotton hulls from Texas and rice hulls from Arkansas) to create a strong composite material.
The material is currently being used for shipping and insulating, but in the future you may see it on your TV or in your car.
I called Bayer Monday at his office in Green Island, NY. Excerpts of our conversation are below.
Ecovative COO Ed Browka, CEO Eben Bayer and Chief Scientist Gavin Mcintyre after winning the Picnic Green Challenge in The netherlands.
(and often paid for) on a device-by-device basis . Which means that for the time being it a bit of a stretch to say...
Traditional storage isn practical for this demographic as it expensive and difficult to access on a weekly or even daily basis. Companies like Boxbee (a Metamorphic portfolio company), Makespace, Urbin, Clutter,
(or might not) is that technology is cited as one of today most fraudulent industries along with pharmaceuticals.
Doctors prescribe antidepressants in the Beehive state at nearly twice the average rate in the U s. Speculation as to
its Scanaflow device is an at home urine-testing apparatus that can test for drugs or even a possible pregnancy. lot more healthcare is going to happen in the home in the future,
and make the loans they want to on an a la carte basis, Ellman says. The marketplace model has been proven,
a first that could allow researchers to test drugs on working muscle without damaging a live host.
biochemical signals and pharmaceuticals. he beauty of this work is that it can serve as a test bed for clinical trials in a dish,
and responds to drugs just like regular human muscle as replacements for lost musculature, which suggests the samples are still too small to be useful.
and it looks like it will be a real boon for researchers trying to figure out the effects of various diseases and drugs on the body.
Not sure if that pill youe taking is Aspirin or Ibuprofen? Worried that your local pharmacy is slipping you some sort of generic drug instead of the real thing?
Well a new handheld scanning device called SCIO could ensure that the stuff youe putting in your body is actually stuff you want to ingest.
but powerful scanner that can be pointed at a thing like a pill or a liquid or even a piece of fruit and tell you exactly what it made of.
and drugs they eat. Using near infrared spectroscopy the device connects with a mobile app
whether your dealer pharmacist is honest about what theye selling to you. We chatted with the chief happiness officer of parent company Consumer Physics about the device and what it capable of.
The Regulatory Pathwaythe U s. Food & Drug Administration (FDA) has created three categories of MMAS: Of more than 43000 health-related apps available by 2013 only 103 were regulated FDA Tighe says.
The Regulatory Pathwaythe U s. Food & Drug Administration (FDA) has created three categories of MMAS: Of more than 43000 health-related apps available by 2013 only 103 were regulated FDA Tighe says.
That because just a month earlier, in November 2013, the Food and Drug Administration had cracked down on 23andme.
or take a drug overdose. Critics of the decision said it had more to do with questions about
or lower, their risk for drug reactions, common diseases, or personality traits such as a lack of empathy.
and avoid drugs like Novocain. think that how people should be using thiss a conversation-starter with medical professionals,
Ello on the other hand positions itself as an antidote to that: it doesn t include any ads and one of several manifestos posted on the site says that those behind Ello dislike ads more than almost anyone else out there.
#Gene-Silencing Drugs Finally Show Promise The disease starts with a feeling of increased clumsiness.
because it suggested a way to shut down the production of any protein in the body including those connected with diseases that couldn't be touched with ordinary drugs.
Never mind that no one knew how to make a drug that could trigger RNAI. In fact that challenge would bedevil the researchers for the better part of a decade.
But now Alnylam is testing a drug to treat FAP in advanced human trials. It s the last hurdle before the company will seek regulatory approval to put the drug on the market.
Although it s too early to tell how well the drug will alleviate symptoms it s doing
what the researchers hoped it would: it can decrease the production of the protein that causes FAP by more than 80 percent.
Alnylam has more than 11 drugs including ones for hemophilia Hepatitis b and even high cholesterol in its development pipeline and has three in human trials progress that led the pharmaceutical company Sanofi to make a $700 million investment in the company last winter.
Last month the pharmaceutical giant Roche an early Alnylam supporter that had given up on RNAI reversed its opinion of the technology as well announcing a $450 million deal to acquire the RNAI startup Santaris.
All told there are about 15 RNAI-based drugs in clinical trials from several research groups and companies.
The world went from believing RNAI would change everything to thinking it wouldn t work to now thinking it will says Robert Langer a professor at MIT and one of Alnylam s advisors.
The early mechanisms were too toxic at the doses required to be used as drugs. As a result delivering RNA through the bloodstream like a conventional drug seemed a far-off prospect.
The company tried a shortcut of injecting chemically modified RNA directly into diseased tissue for example into the retina to treat eye diseases.
because it didn t perform as well as up-and-coming drugs from other companies. By 2010 some of the major drug companies that were working with and investing in Alnylam lost patience.
Novartis decided not to extend a partnership with Alnylam; Roche gave up on RNAI altogether. Alnylam laid off about a quarter of its workers
Better nanoparticles improved the potency of a drug a hundredfold and its safety by about five times clearing the way for clinical trials for FAP a crucial event that kept the company alive.
This approach allows for the drug to be administered with a simple injection that patients could give themselves at home.
In addition to being easier to administer the new sugar-based drugs are potentially cheaper to make.
For all of their benefits the drug delivery mechanisms Alnylam uses have one flaw they re effective only for delivering drugs to liver cells.
but if it maintains its momentum the drugs currently in clinical trials could represent just a small portion of the benefits of the discovery of RNAI i
And while wee still far from turning new insights into effective and safe drugs at least the emerging knowledge is giving researchers some options in exploring potential treatments.
drug researchers might be able to zero in on specific common pathways or types of cells in attempts to tackle these disorders.
which manages pharmacy benefits for 90 million members in the U s . and processes 1. 4 billion prescriptions a year, has scoured its data from doctorsoffices, pharmacies,
and laboratories to detect patterns that might alert doctors to potential adverse drug interactions and other prescription issues.
Doctors can now know 12 months in advance, with an accuracy rate of 98 percent, which of their patients may fail to take their medicine.
the scientists who authored the editorial say society needs to develop ntegrated risk managementincluding genetic antidotes that could reverse the effect,
the basis of all computing today. his is our attempt to find the analogous device to the transistor,
The theoretical basis of topological qubits was sketched first out at UC Santa barbara roughly eight years ago,
the U s. Food & Drug Administration approved Neuropace, the first implant that both records from the brain and stimulates it (see apping Seizures Away.
and who can be helped with drugs and psychotherapy. his is never going to be a first-line option:
Researchers have speculated for decades that a drug that could inhibit IDE might help some type 2 diabetes patients.
Small-molecule drugs, which make up the majority of medicines, are compounds far smaller than less common biological medicines like antibodies.
which may be why the Harvard team was able to identify an IDE-controlling drug when so many had failed in the past.
The newly identified IDE inhibitor could be the starting point for developing a powerful new drug for type 2 diabetes.
#Nerve-Stimulating Implant Could Lower Blood pressure An implantable device that reduces blood pressure by stimulating a nerve in the neck could someday be an alternative to drugs for controlling hypertension.
Up to 30 percent of people with high blood pressure cannot be treated fully with medication and some patients taking the drugs suffer from side effects including fatigue and lightheadedness.
An implantable device would allow reducing the blood pressure in these patients either alone or in combination with the already applied medication says Dennis Plachta a microsystems engineer at the University of Freiburg in Germany.
It offers a second chance not available yet and it can run in a tandem solution to a pharmaceutical treatment.
Plachta and his team developed a micromachined cuff that wraps around the vagal nerve a nerve found in the neck that exchanges critical physiological information between the brain
He says all his patients are on several blood pressure medications and some find that side effects make the drug regimens difficult to maintain.
The worst part is that the blood pressure is still high which means they are at high risk for stroke heart failure
Kristoffer Famm vice president of bioelectronics research and development at Glaxosmithkline coauthored a paper last year on the emergence of the field that he and his academic colleagues call electroceuticals.
Whereas drugs cannot adapt to patient activities an intelligent implant can he says which could offer a way to treat hypertension on demand d
Those new data streams could form the basis for many new services and products, but they also bring new privacy concerns.
These ads target coupons on the basis of actions taken in a mobile app, such as completing a game.
The methods developed to create the designer genomic structure could help synthetic biologists better use the single-celled fungi as biological factories for chemicals like biofuels and drugs.
or perhaps be better factories for useful molecules like fuels and drugs. Already the researchers have shown that inducing mutation in yeast using the designer sites led to some cells that grow more slowly,
#New Antibiotic from Soil Bacteria Many of the most widely used antibiotics have come out of the dirt.
Now, researchers from Northeastern University and Novobiotic Pharmaceuticals and their colleagues have identified a new Gram-positive bacteria-targeting antibiotic from a soil sample collected in Maine that can kill species including methicillin-resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis.
Moreover, the researchers have not yet found any bacteria that are resistant to the antibiotic, called teixobactin.
microbiologist Kim Lewis, director of Northeastern Antimicrobial Discovery Center. But mice treated with teixobactin after lethal doses of either MRSA
That the antibiotic can kill M. tuberculosis s a major breakthrough because it is virtually certain to be effective for the multi-resistant strains that are now all but impossible to treat,
Although further studies are needed before the antibiotic can be tested in humans animal efficacy models are often predictive of a drug effects in humans,
said Gerard Wright, director of the Institute for Infectious disease Research at Mcmaster University in Hamilton, Canada,
said Wright. his biodiversity is also hiding a lot of chemical diversity that may include other new antibiotics. his is a very clever technique, added Robert Austin,
because this will not lead to new antibiotics. Rather than targeting a protein whose gene is mutable,
said Lewis. A related antibiotic, vancomycin, binds to a mutable peptide added to the peptidoglycan precursor.
Vancomycin-producing Gram-positive bacteria make an alternative peptide to outmaneuver the antibiotic, produced to target other Gram-positive species. Some Gram-positive bacteria acquired this alternative peptide-coding gene through horizontal gene transfer over the course of around 30 years,
providing us with a new strategy for antibiotic development, he added. Cambridge-based Novobiotic Pharmaceuticals,
which Lewis co-founded, is now using this cultivation technique to identify other potential antibiotic compounds
and to develop a more soluble version of teixobactin. Still Austin emphasized that teixobactin resistance is likely to emerge. ork we
I would caution people to not be overly optimistic until we see what happens in realistic clinical settings. he rate of evolution of large-scale resistance will depend on the dosage and frequency of the antibiotic use, added Princeton microbiologist Julia Bos, a member
Assuming the antibiotic is efficacious and well tolerated in humans, drug like this must be reserved for serious diseases
but also expedite the drug development process, "Dr Mandal said. Dr Kameshwar Prasad, professor and head of neurology at AIIMS, said the findings are preliminary."
Early identification can help in giving drug therapy to slow the degeneration process and develop strategies to enhance the patient's living environment,
Several recently developed drugs--bevacizumab, ranibizumab and aflibercept--can help treat these blood vessels by blocking the action of VEGF,
But studies have shown that although these drugs slow progression to proliferative diabetic retinopathy, it does not reliably prevent it,
Sodhi suggested if a drug can be found that safely blocks the second protein's action in patients'eyes
Several recently developed drugs--bevacizumab, ranibizumab and aflibercept--can help treat these blood vessels by blocking the action of VEGF,
But studies have shown that although these drugs slow progression to proliferative diabetic retinopathy, it does not reliably prevent it,
Sodhi suggested if a drug can be found that safely blocks the second protein's action in patients'eyes
Using the invention on carboplatin a common cancer treatment drug, used against ovarian and lung cancers has boosted the potency by almost five times.
"The tool can be used to take away the wastage in a drug, meaning that you need less of it to do the same work.
and could mean that the drugs treat tumours much more effectively. As well as helping with treatment, the tool could cut down the wastage created during the process of making drugs.
That could make the pharmaceutical much more sustainable and reduce their impact on the environment.
More of the devices are being made, reports ABC News, and will be sent to other researchers in Australia and elsewhere.
Using the invention on carboplatin a common cancer treatment drug, used against ovarian and lung cancers has boosted the potency by almost five times.
"The tool can be used to take away the wastage in a drug, meaning that you need less of it to do the same work.
and could mean that the drugs treat tumours much more effectively. As well as helping with treatment, the tool could cut down the wastage created during the process of making drugs.
That could make the pharmaceutical much more sustainable and reduce their impact on the environment.
More of the devices are being made, reports ABC News, and will be sent to other researchers in Australia and elsewhere.
have been developed into successful drugs. It is hoped that T-VEC could be used in combination with these.
have already been submitted to drugs regulators in Europe and the USA. Viral immunotherapies are also being investigated for use against advanced head and neck cancers, bladder cancers and liver cancers.
have been developed into successful drugs. It is hoped that T-VEC could be used in combination with these.
have already been submitted to drugs regulators in Europe and the USA. Viral immunotherapies are also being investigated for use against advanced head and neck cancers, bladder cancers and liver cancers.
This is an important step for the future production of large numbers of these cells for use in cell transplantation therapies or large-scale drug screens, researchers from the Molecular Medicine Institute in Lisbon,
#Engineered E coli to fight antibiotic-resistant bacteria WASHINGTON: Researchers have engineered successfully E coli bacteria to produce new forms of antibiotics including three that show promise in fighting drug-resistant bacteria.
Blaine A Pfeifer, an associate professor of chemical and biological engineering in the University at Buffalo School of engineering and Applied sciences, has been studying how to engineer Escherichia coli (E coli) to generate new varieties of erythromycin, a popular antibiotic.
In the new study, Pfeifer and colleagues report that they have done this successfully, harnessing E coli to synthesise dozens of new forms of the drug that have a slightly different structure from existing versions.
Three of these new varieties of erythromycin successfully killed bacteria of the species Bacillus subtilis that were resistant to the original form of erythromycin used clinically"We're focused on trying to come up with new antibiotics that can overcome antibiotic resistance,
and we see this as an important step forward, "said Pfeifer.""We have not only created new analogs of erythromycin,
but also developed a platform for using E coli to produce the drug, "he said. Over the past 11 years, Pfeifer's research has focused on manipulating E coli
so that the drug they make is slightly different than versions used in hospitals today. The process of creating erythromycin begins with three basic building blocks called metabolic precursors chemical compounds that are combined
Researchers have engineered successfully E coli bacteria to produce new forms of antibiotics including three that show promise in fighting drug-resistant bacteria.
Blaine A Pfeifer, an associate professor of chemical and biological engineering in the University at Buffalo School of engineering and Applied sciences, has been studying how to engineer Escherichia coli (E coli) to generate new varieties of erythromycin, a popular antibiotic.
harnessing E coli to synthesise dozens of new forms of the drug that have a slightly different structure from existing versions.
Three of these new varieties of erythromycin successfully killed bacteria of the species Bacillus subtilis that were resistant to the original form of erythromycin used clinically"We're focused on trying to come up with new antibiotics that can overcome antibiotic resistance,
but also developed a platform for using E coli to produce the drug, "he said. Over the past 11 years, Pfeifer's research has focused on manipulating E coli
so that the drug they make is slightly different than versions used in hospitals today. The process of creating erythromycin begins with three basic building blocks called metabolic precursors chemical compounds that are combined
which is being called the world's first digital drug, can zap your brain to make you feel
Antiviral antibodies in the blood find and bind to their target epitopes within the displayed peptides.
and needed morphine to make it through the day, "he recalled. But within days of undergoing the operation last October, the pain vanished.
and needed morphine to make it through the day, "he recalled. But within days of undergoing the operation last October, the pain vanished.
The discovery could be used as the basis of a new kind of switching device for future optical computers that use pulses of light rather than electricity to process
The discovery could be used as the basis of a new kind of switching device for future optical computers that use pulses of light rather than electricity to process
#In a first, drug offers hope for children with dwarfism An experimental drug, vying to become the first approved treatment for dwarfism, improved growth in children by a significant amount in a preliminary study, the drug's developer,
Biomarin Pharmaceutical, said on Wednesday. In the study, the 10 children who got the highest dose of the drug grew at an average rate of 6. 1cm,
or 2. 4 inches, per year, about a 50%increase from the four centimetres per year they were growing before starting the drug.
The growth rate while on the drug was similar to that of a child without the condition
the company said. Wall street investors and analysts had been hoping for a 50%improvement in growth rate,
and Biomarin shares rose 6%in after-hours trading. Dr William R Wilcox, a human genetics professor at Emory University, called the results"promising."
a drug already marketed for certain children, can also increase the growth rate for people with dwarfism to 6 centimetres per year
The drug, which is called BMN 111 or vosoritide, is aimed at treating achondroplasia, the most common form of dwarfism.
000 children with the condition in the markets in North america, Europe, Asia and Latin america in which it anticipates selling the drug.
The drug would not be expected to work in adults because they have stopped growing. Women with achondroplasia typically grow to about four feet tall,
The drug is welcomed not universally. Some people with dwarfism say it is not a disease that needs treatment.
but slightly different proteins (immunogens) to train the body to produce broadly neutralizing antibodies against HIV-a twist on the traditional"booster shot,
where a person is exposed to the same immunogen multiple times. The scientists tested one of these potential proteins,
an immunogen called eod-GT8 60mer, using a technique called B cell sorting. The researchers showed that immunisation with eod-GT8 60mer produced antibody"precursors"with some of the traits necessary to recognize
"Pneumonia can be treated with antibiotics but there are two major problems-it can be difficult to detect
and diagnose and because of that we tend to use potent broad spectrum antibiotics in anyone who shows symptoms of infection,
Understanding the pathways the parasite uses means that future drugs could be designed precisely to kill the parasite but with limited toxicity
with the parasite continually working to find ways to survive our drug treatments. This study opened the door on potential new treatments that could find
The findings also provide strong evidence that certain type-2 diabetic drugs, belonging to a new class known as SGLT2 inhibitors
and Drug Administration and were launched recently in India, could potentially block glucose uptake and reduce tumour growth and increase survival among pancreatic and prostate cancer patients.
They hope that these findings will lead to the potential use of the existing antidiabetic medicines to reduce the viability of pancreatic and prostate cancer cells
and progression to AIDS that you would expect without drug therapy, "said lead author Giovanna Rappocciolo, assistant professor at University of Pittsburgh in the US.
"These results improve understanding of how nonprogressors control HIV without drug therapy and potentially may contribute to new approaches to manage HIV infection,"Rappocciolo added.
#utated lepto bacteria resistant to drugs, heatmumbai: Scientists at the premier Regional Medical Reference Centre (RMRC) at Port Blair have found that the bacterial species that causes leptospirosis is no longer socially aloof,
when attacked with normal doses of antibiotics, ultraviolet radiation or even heat. Understanding leptospira's mutation,
some of the leading antibiotics used to treat acute leptospirosis in humans and animals,"said Dr Paluru Vijayachari, director of the Port Blair institute."
With that level of backing it can even be expected that these organisations will rise to the to the top of the field of 3d printed generative medication studies.
This new round of investments is great news for the development of 3d printed medication
"The fourth day after surgery I envisioned her still being on a breathing machine in the ICU getting massive amounts of medication,
and intricately patterned shapes that could ultimately lead to injectable materials for delivering drugs or cells into the human body.
Among other applications for the automated DNA folding process include helping researchers develop nanoscale structures for targeted drug delivery
including drug delivery systems, possibly in the next 5 to 10 years. i
#3d printed smartphone device reads ELISA diagnostic tests accurately and within one minute In remote or developing countries,
Our next development will be an Endolif Cage on the basis of our ilessys Delta system for posterior lumbar inter-body fusion (PLIF.
On the basis of the game you play, the Lyteshot performs accordingly. For example, it can deliver a deadly blow to an enemy,
#CAP-XX Introduces Thinline Supercapacitors with Unique Nanotechnology Construction Examples include wearables (medical, fitness and health monitors, smart watches, drug delivery systems), portables (active
or a group of molecules when researchers treat an organism with active pharmaceutical ingredients. Embryo development could also be examined in more detail."
A promising area of use seems to be the transport of drugs to specific areas of the body.
This sort of'smart'container for medicines could carry out carefully planned drug therapy in a selected organ in the human body.
The project goal is to develop new tools to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days from exposure.
#Graphene-Coated Catheters May Improve Delivery of Chemotherapy drugs The research suggests that placing graphene-an extremely thin sheet of carbon atoms-on the internal surfaces of intravenous catheters commonly used to deliver chemotherapy drugs into a patient's body will improve the efficacy of treatments,
The study indicates that damaging interactions can occur between the most commonly used chemotherapy drug, 5-Fluorouracil (5-Fu),
As a result of this damage the researchers believe the drug may not deliver the desired therapeutic effect in patients
nobody has looked ever at the chemical reaction between chemotherapy drugs and the materials they routinely come into contact with, such as catheters and needles and their coatings.
It is assumed just that the drugs are delivered into the body intact.""We have shown that silver is catalytically degrading the chemotherapy drugs,
which means they are probably not being delivered correctly into the patient. Our research indicates that one of the decay products of this reaction is HF,
as well as the drug's reactions with silver and graphene. XPS is used a technique to measure the surface chemistry of a particular material by firing a beam of x-rays at it
which there is a massive loss of the element fluoride from the drug, leading to the creation of HF.
and that graphene caused no damage to the drug. Graphene is a biocompatible material with low toxicity that has already been suggested as an external coating for biomedical applications.
Together with our collaborators and students, we are increasing our understanding of the critical interactions between drugs and medical coatings,
We will also look to extend our experiments to include other chemotherapy drugs.""Source: http://ioppublishing. org g
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011